Plain-English translation of NCT06510374 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new gene therapy called for people who have been diagnosed with intermediate-risk non-muscle invasive bladder cancer. Half of participants will receive quarterly doses of the medication directly into the bladder over 24 months, while the other half will receive standard monitoring with regular check-ups. The goal is to see whether this new treatment can help prevent cancer from coming back.
Intermediate-risk bladder cancer often recurs even after surgery, and doctors are looking for better ways to prevent it from returning. This trial is testing whether the medication can reduce recurrence rates better than monitoring alone.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to one of two groups. If assigned to receive the medication, you will visit the clinic every three months for 24 months to receive doses of the treatment instilled directly into your bladder. If assigned to standard monitoring, you will have regular check-up visits every three months to watch for any signs of cancer returning. Both groups will have similar follow-up appointments to check your bladder health; the main difference is whether you receive the new medication or standard care alone.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States